Home > Insider Trading > Filing (0001493152-24-021176)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1708599	Serina Therapeutics Inc.	SER	Pharmaceutical Preparations (2834)	821436829

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
2008741	Steven Mintz	601 Genome Way, Suite 2001 Huntsville AL 35806		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-05-17	554	$8.50	554	No	4	P	Indirect	By Spouse
Common Stock	Acquisiton	2024-05-20	195	$9.48	749	No	4	P	Indirect	By Spouse
Common Stock	Acquisiton	2024-05-21	6,651	$10.00	7,400	No	4	P	Indirect	By Spouse
Common Stock	Acquisiton	2024-05-21	2,500	$9.75	9,900	No	4	P	Indirect	By Spouse
Common Stock	Acquisiton	2024-05-20	1,240	$9.44	1,240	No	4	P	Indirect	By Adult Child 1
Common Stock	Acquisiton	2024-05-20	1,240	$9.42	1,240	No	4	P	Indirect	By Adult Child 2

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Spouse
No	4	P	Indirect	By Spouse
No	4	P	Indirect	By Spouse
No	4	P	Indirect	By Spouse
No	4	P	Indirect	By Adult Child 1
No	4	P	Indirect	By Adult Child 2

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	3,307	Direct

Footnotes

The Reporting Person may be deemed to share voting, investment and dispositive power with respect to these securities. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
The Reporting Person may be deemed to share voting, investment and dispositive power with respect to these securities. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
Number of securities determined after giving effect to a reverse split of the Issuer's common stock of 1-for-35.17.